Crowdonomics
All companies

Aclarion, Inc.

Public

Healthcare · Broomfield, CO

Estimated pre-money ⓘ
$13.8M
As of Jun 2024 · from Reg A Offering (2024) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$11,684,800
Crowd $0 · Private $11.7M · 7 rounds since 2015
Latest share price
$0.73
Reg A Offering (2024) offering price

Financials

FY2021–FY2025 · from SEC filings · hover any figure for its source
$60K
−$5.0M
2021
$60K
−$7.6M
2022
$75K
−$4.9M
2023
$46K
−$7.0M
2024
$76K
−$7.2M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021 audited
FY2022 audited
FY2023 audited
FY2024 audited
FY2025 audited
Income statement
Revenue
$60,292
$60,444
$75,404
$45,724
$75,730
Cost of goods sold
$69,175
$65,298
$75,728
$84,658
$68,902
Gross margin
-15%
-8%
0%
-85%
9%
Net income
-$4,950,290
-$7,605,542
-$4,911,374
-$6,992,927
-$7,233,629
Taxes paid
$0
$0
$0
$0
$0
Balance sheet
Cash
$432,530
$1,472,806
$1,021,069
$453,661
$12,015,789
Accounts receivable
$6,280
$18,569
$13,270
$18,326
$29,680
Total assets
$1,889,465
$3,205,961
$2,459,774
$2,123,483
$13,672,404
Short-term debt
$2,000,000
$0
—
—
—
Long-term debt
—
—
$0
—
—
Total liabilities
$2,000,000
$0
$1,221,812
$1,153,426
$837,287
Other
Headcount
—
—
5
—
—

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$13.8M
est. pre-money
Reg A+ · Equity · Jun 2024

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Jun 30, 2026
ClassOutstandingVotes / shareShare of totalLast price
Common Stock2,462,250—100.0%—

Shares outstanding over timein today's share terms

2.5M1.2M0
Dec 2021Jun 2026
Common StockSeries A preferred stockSeries B Preferred StockSeries B-1 Preferred StockSeries B-2 Preferred StockSeries B-3 Preferred StockRound openedSplit / conversion

Changes in named holdersshares in today's terms · % of all shares at the time

Principal holders% as the filing states it, Apr 9, 2025

  • Brent Ness3 Common Stock—of votes
  • David Neal2 Common Stock—of votes
  • Jeff Thramann10 Common Stock—of votes
  • John Lorbiecki1 Common Stock—of votes
  • William Wesemann1 Common Stock—of votes

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $1MInvestors 3
Raised $0 / $75MEst. pre-money $13.8M
Raised $2MInvestors 2
Raised $2MInvestors 4
Raised $1.4MInvestors 12
Raised $3.3MInvestors 14
Raised $2MInvestors 1

Team

9 people
Brent Ness
Chief Executive Officer, President and Director
John Lorbiecki
Chief Financial Officer
Ryan Bond
Chief Strategy Officer
Jeff Thramann, M.D.
Executive Chairman and Director
Amanda Williams
Director
David Neal
Director
Scott Breidbart, M.D.
Director
Steve Deitsch
Director
William Wesemann
Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

  • Form 10-QAug 6, 20260001683168-26-006026
    EDGAR
  • Form 10-QMay 13, 20260001683168-26-003822
    EDGAR
  • Form 10-KMar 18, 20260001683168-26-001986
    EDGAR
  • Form 10-QNov 12, 20250001683168-25-008169
    EDGAR
  • Form 10-QAug 14, 20250001683168-25-006126
    EDGAR
  • Form 10-QMay 15, 20250001683168-25-003594
    EDGAR
  • Form 10-KApr 9, 20250001683168-25-002351
    EDGAR
  • Form 10-QNov 14, 20240001683168-24-008063
    EDGAR
Source: SEC EDGARCIK 0001635077DEShare price $0.73Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.